{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:08:11Z","timestamp":1784099291032,"version":"3.55.0"},"reference-count":27,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13195","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:32:57Z","timestamp":1780054377000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Tumor Treating Fields modulate apoptotic and immune programs in T\u2011cell acute lymphoblastic leukemia cell lines"],"prefix":"10.3892","volume":"32","author":[{"given":"Jinju","family":"Heo","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Korea University, Seoul 02841, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myonggeun","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Korea University, Seoul 02841, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"key20260715092700_b1-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/2643-3230.BCD-20-0093","article-title":"T-cell acute lymphoblastic leukemia: A roadmap to targeted therapies","volume":"2","author":"Cordo","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"key20260715092700_b2-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3324\/haematol.2024.285643","article-title":"Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"110","author":"Hughes","year":"2025","journal-title":"Haematologica"},{"key":"key20260715092700_b3-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"},{"issue":"mjac047","key":"key20260715092700_b4-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjac047","article-title":"Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields])","volume":"14","author":"Shams","year":"2022","journal-title":"J Mol Cell Biol"},{"key":"key20260715092700_b5-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"key20260715092700_b6-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","article-title":"Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): A randomised, open-label, pivotal phase 3 study","volume":"24","author":"Leal","year":"2023","journal-title":"Lancet Oncol"},{"key":"key20260715092700_b7-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1200\/JCO-25-00746","article-title":"Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: Randomized, open-label, pivotal phase III PANOVA-3 study","volume":"43","author":"Babiker","year":"2025","journal-title":"J Clin Oncol"},{"issue":"861","key":"key20260715092700_b8-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11339-7","article-title":"Alternating electric fields can improve chemotherapy treatment efficacy in blood cancer cell U937 (non-adherent cells)","volume":"23","author":"Homami","year":"2023","journal-title":"BMC Cancer"},{"issue":"850571","key":"key20260715092700_b9-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.850571","article-title":"Healing field: using alternating electric fields to prevent cytokine storm by suppressing clonal expansion of the activated lymphocytes in the blood sample of the COVID-19 patients","volume":"10","author":"Abadijoo","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"e210013","key":"key20260715092700_b10-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.2142\/biophysico.bppb-v21.0013","article-title":"Optimizing tumor treating fields for blood cancer therapy: Analysis of electric field distribution and dose density","volume":"21","author":"Nasori","year":"2024","journal-title":"Biophys Physicobiol"},{"key":"key20260715092700_b11-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"3021","key":"key20260715092700_b12-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123021","article-title":"Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia","volume":"20","author":"Follini","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20260715092700_b13-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/jjco\/hyad001","article-title":"Safety and efficacy of tumor treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the NovoTTF system: A prospective post-approval study","volume":"53","author":"Nishikawa","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"key20260715092700_b14-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11864-025-01320-w","article-title":"Tumor treating fields (TTFields) therapy in unresectable pleural mesothelioma: Overview of efficacy, safety, and future outlook","volume":"26","author":"Ceresoli","year":"2025","journal-title":"Curr Treat Options Oncol"},{"key":"key20260715092700_b15-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"181","DOI":"10.6004\/jadpro.2025.16.5.3","article-title":"Tumor treating fields: An innovative therapy for glioblastoma and other solid tumors","volume":"16","author":"Serventi","year":"2025","journal-title":"J Adv Pract Oncol"},{"key":"key20260715092700_b16-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2478\/raon-2023-0044","article-title":"A review of tumor treating fields (TTFields): Advancements in clinical applications and mechanistic insights","volume":"57","author":"Li","year":"2023","journal-title":"Radiol Oncol"},{"issue":"30611","key":"key20260715092700_b17-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-16341-6","article-title":"Tumor treating fields suppress tumor cell growth and induce immunogenic cell death biomarkers in biliary tract cancer cell lines","volume":"15","author":"Yue","year":"2025","journal-title":"Sci Rep"},{"issue":"1413236","key":"key20260715092700_b18-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1413236","article-title":"Tumor treating induced fields: A new treatment option for patients with glioblastoma","volume":"15","author":"Cai","year":"2024","journal-title":"Front Neurol"},{"key":"key20260715092700_b19-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","article-title":"NF-\u03baB in inflammation and cancer","volume":"22","author":"Mao","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"eadh0439","key":"key20260715092700_b20-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adh0439","article-title":"CBL-B mitigates the responsiveness of na\u00efve CD8(+) T cells that experience extensive tonic T cell receptor signaling","volume":"17","author":"Eggert","year":"2024","journal-title":"Sci Signal"},{"issue":"e005845","key":"key20260715092700_b21-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005845","article-title":"Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets","volume":"11","author":"Laletin","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"e2302175","key":"key20260715092700_b22-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302175","article-title":"Cell granularity reflects immune cell function and enables selection of lymphocytes with superior attributes for immunotherapy","volume":"10","author":"Wu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"76","key":"key20260715092700_b23-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2016.00076","article-title":"Flow cytometry-based assessment of mitophagy using MitoTracker","volume":"10","author":"Xiao","year":"2016","journal-title":"Front Cell Neurosci"},{"key":"key20260715092700_b24-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"275","DOI":"10.20455\/ros.2017.839","article-title":"Measurement of mitochondrial mass by flow cytometry during oxidative stress","volume":"4","author":"Doherty","year":"2017","journal-title":"React Oxyg Species (Apex)"},{"key":"key20260715092700_b25-ETM-32-2-13195","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3969\/j.issn.1673-5374.2013.21.009","article-title":"Oxidative stress, mitochondrial damage and neurodegenerative diseases","volume":"8","author":"Guo","year":"2013","journal-title":"Neural Regen Res"},{"issue":"671","key":"key20260715092700_b26-ETM-32-2-13195","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-1042-9","article-title":"NRARP displays either pro- or anti-tumoral roles in T-cell acute lymphoblastic leukemia","volume":"10","author":"Gonz\u00e1lez-Garc\u00eda","year":"2019","journal-title":"Cell Death Dis"},{"issue":"3921","key":"key20260715092700_b27-ETM-32-2-13195","article-title":"Metabolic heterogeneity defines distinct vulnerabilities in T-cell acute lymphoblastic leukemia","volume":"25","author":"Alabed","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:27:09Z","timestamp":1784096829000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,29]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13195","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}